Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    D'Amico Risk Classification for Prostate Cancer

    Assesses 5 year risk of treatment failure based on clinical factors.
    Favorite
    Pearls/Pitfalls

    Developed in 1998, estimates risk of prostate cancer recurrence (low, medium or high) from PSA level, Gleason Score, and tumor stage. May be less accurate in men with multiple risk factors.

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    With changing treatment patterns, there is a large variation on how to treat different risk groups. Low risk patients seem to do well with many treatment modalities. Intermediate risk patients are a very variable group, where further understanding of risk of cancer “beyond the gland” may be necessary to guide treatment. High risk groups often do best with a multimodal treatment approach.

    Dr. Anthony D'Amico

    About the Creator

    Anthony D'Amico, MD, PhD, is professor of radiation oncology at Harvard Medical School. He is also chief of the Division of Genitourinary Radiation Oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. Dr. D'Amico's notable research involves the detection, staging, and treatment of prostate cancer, with over 140 peer-reviewed publications and four co-edited textbooks.

    To view Dr. Anthony D'Amico's publications, visit PubMed